NeoGenomics (NEO)
Runs cancer diagnostic laboratories serving community oncologists, pathologists, and pharmaceutical trial sponsors.
Something off on this page? Send us feedback.
Operates a single-segment network of cancer diagnostics laboratories built through a decade of acquisitions, running cytogenetics, molecular, and liquid-biopsy tests for community oncologists and pathologists while also running contract testing for pharmaceutical sponsors of cancer trials. Revenue depends on payer reimbursement for genomic panels and channel penetration among community cancer practices.
Runs a network of cancer diagnostics laboratories assembled through a series of acquisitions — Clarient, Genoptix, Inivata, and Pathline among them — testing for cytogenetic, immunohistochemistry, flow cytometry, and next-generation-sequencing markers used in cancer diagnosis and monitoring. Clinical testing for community oncologists and pathologists sits alongside contract testing and data services for pharmaceutical companies running cancer trials, now managed as one reportable segment.
Laboratory operations concentrate in the United States, spanning Florida, California, Tennessee, Texas, and New Jersey, with a smaller international presence in Switzerland and the United Kingdom.
Growth depends on reimbursement from Medicare and commercial payers for genomic test panels and on expanding share among community cancer practices. The RaDaR minimal-residual-disease liquid-biopsy assay remains under a permanent injunction stemming from a competitor's patent infringement suit.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 29, 2026 | Craig-Hallum | Reiterate | Rating: —Target: — | Target: $19 |
| Apr 29, 2026 | Leerink Partners | Upgrade | Target: $14 | Target: $25 |
| Apr 29, 2026 | Benchmark | Upgrade | ||
| Feb 24, 2026 | Piper Sandler | Reiterate | Rating: —Target: $11 | Target: $13 |
| Oct 28, 2025 | Leerink Partners | Target | Target: — | Target: $14 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $145.5M · Total debt $448.4M · Total assets $1.35B · Shareholders' equity $785.7M
- Revenue
- $201.7M
- Operating income
- −$9.8M
- Net income
- $2.2M
No dividends on record.
| Institutions | 113.81% | 146.22M shares | |
|---|---|---|---|
| 278 holders · as of Jun 30, 2026 | |||
| Insiders | 6.47% | 8.31M shares | |
| 18 holders · as of Sep 3, 2026 | |||
| Adds to | 120.28% | ||
128.48M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (128.48M in the company's Sep 22, 2026 report, 25.70M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 120.28%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.24% | 20.87M | as of Jun 30, 2026 |
First Light Asset Management, LLCInstitution | 9.56% | 12.28M | as of Jun 30, 2026 |
First Trust Advisors LPInstitution | 7.87% | 10.11M | as of Jun 30, 2026 |
First Trust Portfolios L.P.Institution | 7.87% | 10.11M | filed Jul 30, 2026 |
Greenhouse Funds LLLPInstitution | 6.67% | 8.57M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Greg D. Aunan | officer: Chief Accounting Officer | −20,000 | $16.07 |
| Jun 15, 2026 | Lynn A. Tetrault | director | −5,307 | $11.10 |
| Jun 9, 2026 | Lynn A. Tetrault | director | −5,307 | $11.29 |
| Jan 20, 2026 | Warren Stone | officer: Pres & Chief Operating Officer | −22,128 | $12.50 |
| Nov 25, 2025 | Alicia C. Olivo | officer: EVP, GC & Business Development | −20,916 | $12.00 |
- Natera
Dominant MRD rival — Signatera vs RaDaR, plus years of patent litigation
- Guardant Health
MRD, liquid biopsy, and pharma-data overlap via Guardant Reveal and Guardant360
- Tempus AI
Fast-growing NGS, liquid biopsy, and AI-driven pharma-data rival
- Labcorp
Much larger diversified lab and CRO with an oncology NGS and MRD testing arm
- Quest Diagnostics
Diversified national lab with a growing oncology and MRD testing arm
- Myriad Genetics
Narrower rival in hereditary cancer risk and tumor HRD companion diagnostics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NeoGenomics | $19.28 | −0.69% | $498.7M | — | 69.3 | 0.7 | +11.2% |
| Natera | $385.65 | +4.05% | $53.08B | — | — | 19.6 | +37.7% |
| Guardant Health | $178.36 | +2.58% | $23.33B | — | — | 19.7 | +44.3% |
| Tempus AI | $78.91 | +1.12% | $13.67B | — | — | 9.5 | +21.6% |
| Labcorp | $309.13 | −3.69% | $26.32B | 26.6 | 16.3 | 1.8 | +5.8% |
| Quest Diagnostics | $232.80 | −4.93% | $27.03B | 26.0 | 20.3 | 2.3 | +10.2% |
| Myriad Genetics | $3.97 | −1.12% | $378.7M | — | — | 0.5 | −10.5% |
| Median | 26.3 | 18.3 | 5.9 | +15.9% |